Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay. Beranger N, Benghezal S, Joly BS, Capdenat S, Delton A, Stepanian A, Coppo P, Veyradier A. Res Pract Thromb Haemost. 2020 Dec 15;5(1):81-93.

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura. Graça NAG, Ercig B, Carolina Velásquez Pereira L, Kangro K, Kaijen P, Nicolaes GAF, Veyradier A, Coppo P, Vanhoorelbeke K, Männik A, Voorberg J. Haematologica. 2020 Nov 1;105(11):2619-2630.

Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment. Barba C, Peyre M, Galicier L, Cathebras P, Ranta D, Malot S, Veyradier A, Coppo P. Br J Haematol. 2020 Nov 20. doi: 10.1111/bjh.17170. Epub ahead of print. PMID: 33216951.

A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bigé N, Poullin P, Provôt F, Martis N, Presne C, Moranne O, Benainous R, Dossier A, Seguin A, Hié M, Wynckel A, Delmas Y, Augusto JF, Perez P, Rieu V, Barbet C, Lhote F, Ulrich M, Charvet Rumpler A, De Witte S, Krummel T, Veyradier A, Benhamou Y. Blood. 2020 Nov 4:blood.2020008021. doi: 10.1182/blood.2020008021. Epub ahead of print. PMID: 33150928.

Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab. Mellaza C, Henry N, Fayolle PM, Mortaza S, Subra JF, Veyradier A, Coppo P, Augusto JF. Front Med (Lausanne). 2020 Oct 22;7:549931. doi: 10.3389/fmed.2020.549931. PMID: 33195299; PMCID: PMC7649819.

Efficacy of subcutaneous preemptive rituximab in immune-mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases. Delrue M, Baylatry MT, Joly AC, Corre E, Marjanovic Z, El-Khoury-Hanna N, Féger F, Suner L, Veyradier A, Stépanian A, Coppo P. Am J Hematol. 2020 Oct 17. doi: 10.1002/ajh.26022. Epub ahead of print. PMID: 33068040.

HLA-DRB1*11 is a strong risk factor for acquired thrombotic thrombocytopenic purpura in children. Joly BS, Loiseau P, Darmon M, Leblanc T, Chambost H, Fouyssac F, Guigonis V, Harambat J, Stepanian A, Coppo P, Veyradier A. Haematologica. 2020 Jan 16;105(10):241968. doi: 10.3324/haematol.2019.241968. Epub ahead of print. PMID: 31949018; PMCID: PMC7556652.

Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura. Pereira LCV, Ercig B, Kangro K, Jamme M, Malot S, Galicier L, Poullin P, Provôt F, Presne C, Kanouni T, Servais A, Benhamou Y, Daguindau N, Vanhoorelbeke K, Azoulay E, Veyradier A, Coppo P. Hemasphere. 2020 Aug 11;4(4):e462. doi: 10.1097/HS9.0000000000000462. PMID: 32885148; PMCID: PMC7430230.

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Roose E, Schelpe AS, Tellier E, Sinkovits G, Joly BS, Dekimpe C, Kaplanski G, Le Besnerais M, Mancini I, Falter T, Von Auer C, Feys HB, Reti M, Rossmann H, Vandenbulcke A, Pareyn I, Voorberg J, Greinacher A, Benhamou Y, Deckmyn H, Fijnheer R, Prohászka Z, Peyvandi F, Lämmle B, Coppo P, De Meyer SF, Veyradier A, Vanhoorelbeke K. Blood. 2020 Jul 16;136(3):353-361. doi: 10.1182/blood.2019004221. PMID: 32356859.

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. J Thromb Haemost. 2020 Feb;18(2):479-484. doi: 10.1111/jth.14679. Epub 2019 Dec 9. PMID: 31691462; PMCID: PMC7027866.